These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 28867010)

  • 1. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions.
    Naganuma T; Kawamoto H; Panoulas VF; Latib A; Tanaka A; Mitomo S; Ruparelia N; Jabbour RJ; Chieffo A; Carlino M; Montorfano M; Colombo A
    Int J Cardiol; 2017 Nov; 246():26-31. PubMed ID: 28867010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial.
    Orvin K; Carrie D; Richardt G; Desmet W; Assali A; Werner G; Ikari Y; Fujii K; Goicolea J; Dangoisse V; Manari A; Saito S; Wijns W; Kornowski R
    Catheter Cardiovasc Interv; 2016 May; 87(6):1092-100. PubMed ID: 26268482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
    Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
    EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.
    Suwannasom P; Sotomi Y; Ishibashi Y; Cavalcante R; Albuquerque FN; Macaya C; Ormiston JA; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Tijssen JG; Wykrzykowska JJ; de Winter RJ; Chevalier B; Serruys PW; Onuma Y
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1231-1242. PubMed ID: 27262861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry.
    Naganuma T; Colombo A; Lesiak M; Capodanno D; Gori T; Nef H; Caramanno G; Naber C; Di Mario C; Ruparelia N; Capranzano P; Wiebe J; Araszkiewicz A; Geraci S; Kawamoto H; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Latib A
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):47-56. PubMed ID: 27414021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
    Gao R; Yang Y; Han Y; Huo Y; Chen J; Yu B; Su X; Li L; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Xu B; Popma JJ; Stone GW;
    J Am Coll Cardiol; 2015 Dec; 66(21):2298-2309. PubMed ID: 26471805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTAD-ABSORB studies.
    Tarantini G; Masiero G; Barioli A; Paradies V; Vlachojannis G; Tellaroli P; Cortese B; di Palma G; Varricchio A; Ielasi A; Loi B; Steffenino G; Ueshima D; Mojoli M; Smits P
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):E115-E124. PubMed ID: 29513403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions.
    Jabbour RJ; Ielasi A; Tanaka A; Leoncini M; Cortese B; Grigis G; Mitomo S; Regazzoli D; Di Palma G; Rapetto C; Tespili M; Colombo A; Latib A
    Cardiovasc Revasc Med; 2017; 18(5S1):S4-S9. PubMed ID: 28314675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter "real-world" registry.
    Imori Y; D'Ascenzo F; Gori T; Münzel T; Fabrizio U; Campo G; Cerrato E; Napp LC; Iannaccone M; Ghadri JR; Kazemian E; Binder RK; Jaguszewski M; Csordas A; Capasso P; Biscaglia S; Conrotto F; Varbella F; Garbo R; Gaita F; Erne P; Lüscher TF; Moretti C; Frangieh AH; Templin C
    Cardiol J; 2016; 23(4):374-83. PubMed ID: 27515481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
    Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
    JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials.
    Cassese S; Byrne RA; Jüni P; Wykrzykowska JJ; Puricel S; Ndrepepa G; Schunkert H; Fusaro M; Cook S; Kimura T; Henriques JPS; Serruys PW; Windecker S; Kastrati A
    EuroIntervention; 2018 Jan; 13(13):1565-1573. PubMed ID: 28671552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial.
    Tijssen RYG; Kerkmeijer LSM; Katagiri Y; Kraak RP; Takahashi K; Kogame N; Chichareon P; Modolo R; Asano T; Nassif M; Kalkman DN; Sotomi Y; Collet C; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Beijk MAM; Piek JJ; Tijssen JGP; Henriques JP; de Winter RJ; Onuma Y; Serruys PW; Wykrzykowska JJ
    Int J Cardiovasc Imaging; 2019 Jul; 35(7):1189-1198. PubMed ID: 30911857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients.
    Hellenkamp K; Becker A; Gabriel YD; Hasenfuß G; Hünlich M; Jacobshagen C; Schillinger W; Schroeter MR
    Int J Cardiol; 2017 May; 234():58-63. PubMed ID: 28258843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.
    Sorrentino S; Giustino G; Mehran R; Kini AS; Sharma SK; Faggioni M; Farhan S; Vogel B; Indolfi C; Dangas GD
    J Am Coll Cardiol; 2017 Jun; 69(25):3055-3066. PubMed ID: 28412389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.